Targeting JAK3 and BTK Tyrosine Kinases with Rationally-Designed Inhibitors

Title: Targeting JAK3 and BTK Tyrosine Kinases with Rationally-Designed Inhibitors

Volume: 7 Issue: 3

Author(s): Alexei O. Vassilev, Heather E. Tibbles, Darin DuMez, Taracad K. Venkatachalam and Fatih M. Uckun

Affiliation:

Keywords: Rational Drug Design, Tyrosine Kinases, Inhibitors, JAK3, BTK

Abstract: Multifunctional rational drug design of protein tyrosine kinases inhibitors allows a potent drug to be utilized to treat more than one disease for greater patient benefits. Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Brutons tyrosine kinase (BTK), have been identified as potential drug targets to treat diverse diseases including cancer and disorders of the immune system. Here we review advances in JAK3 and BTK inhibitors and describe the therapeutic potential of these potent agents in the clinical setting.

Cite this article as:

Vassilev O. Alexei, Tibbles E. Heather, DuMez Darin, Venkatachalam K. Taracad and Uckun M. Fatih, Targeting JAK3 and BTK Tyrosine Kinases with Rationally-Designed Inhibitors, Current Drug Targets 2006; 7 (3) . https://dx.doi.org/10.2174/138945006776054997